The mechanism of delivery for XHANCE

XHANCE uses an Optinose Exhalation Delivery System (EDS) designed to deliver medication high and deep in the nasal passages to regions where nasal polyps originate and sinuses drain and ventilate.^1,2

View the journey through the nasal anatomy

Video of the journey through the nasal anatomy using the Exhalation Delivery System

View the mechanism of delivery in action

Video of the mechanism of delivery in action using the Exhalation Delivery System

XHANCE was designed with the nasal anatomy in mind

Image of the patented nosepiece of the Exhalation Delivery System sealing tightly in the nostril and creating positive pressure that expands narrow nasal passages

The patented nosepiece is specifically designed to seal tightly in the nostril, act as a stent in the nasal valve, and create positive pressure that expands narrow nasal passages, helping medicine reach high and deep in the nasal passages.³

Image of the Exhalation Delivery System delivering medication to the superior and posterior regions, including the ostiomeatal complex, behind the middle turbinate XHANCE is designed to promote deposition of medication to the superior and posterior regions, including the ostiomeatal complex, behind the middle turbinate, where^1-4:

Sinuses drain and ventilate
Most polyps originate
Inflamed membranes and polyps can obstruct sinuses

Image of the dynamics of the Exhalation Delivery System to elevate and seal the soft palate XHANCE leverages the dynamics of an Optinose EDS to elevate and seal the soft palate, shown here. This may limit medication from dripping down the throat and helps guide the exhaled breath to pass behind the nasal septum and out the opposite nostril.

Photo of Dr. Murphy

“When I explain the anatomy of closing the soft palate for the benefit of bidirectional flow and minimization of medication run-off posteriorly, [my patients] get really excited.

Allergist Thomas Murphy, MD
Paid consultant of Optinose

The clinical trials for XHANCE evaluated over 1500 patients.³

View endoscopy videos taken before and after treatment with XHANCE.

+

References:

Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2023.
Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective — a review. Drug Deliv Transl Res. 2013;3(1):42-62.
Data on file. OptiNose US, Inc.
Newton JR, Ah-See KW. A review of nasal polyposis. Ther Clin Risk Manag. 2008;4(2):507-512.

INDICATIONS

XHANCE is a corticosteroid indicated for the treatment of chronic rhinosinusitis with or without nasal polyps in adults.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS: Hypersensitivity to any ingredient in XHANCE.

WARNINGS AND PRECAUTIONS:

Local nasal adverse reactions, including epistaxis, erosion, ulceration, septal perforation, Candida albicans infection, and impaired wound healing, can occur. Monitor patients periodically for signs of possible changes on the nasal mucosa. Avoid use in patients with recent nasal ulcerations, nasal surgery, or nasal trauma until healing has occurred.
Glaucoma and cataracts may occur with long-term use. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use XHANCE long-term.
Hypersensitivity reactions (e.g., anaphylaxis, angioedema, urticaria, contact dermatitis, rash, hypotension, and bronchospasm) have been reported after administration of fluticasone propionate. Discontinue XHANCE if such reactions occur.
Immunosuppression and infections can occur, including potential increased susceptibility to or worsening of infections (e.g., existing tuberculosis; fungal, bacterial, viral, or parasitic infection; ocular herpes simplex). Use with caution in patients with these infections. More serious or even fatal course of chickenpox or measles can occur in susceptible patients.
Hypercorticism and adrenal suppression may occur with very high dosages or at the regular dosage in susceptible individuals. If such changes occur, discontinue XHANCE slowly.
Assess for decrease in bone mineral density initially and periodically thereafter.

ADVERSE REACTIONS:

Chronic rhinosinusitis without nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, headache, and nasopharyngitis.
Chronic rhinosinusitis with nasal polyps: The most common adverse reactions (incidence ≥ 3%) are epistaxis, nasal septal ulceration, nasopharyngitis, nasal mucosal erythema, nasal mucosal ulcerations, nasal congestion, acute sinusitis, nasal septal erythema, headache, and pharyngitis.

DRUG INTERACTIONS: Strong cytochrome P450 3A4 inhibitors (e.g., ritonavir, ketoconazole): Use not recommended. May increase risk of systemic corticosteroid effects.

USE IN SPECIFIC POPULATIONS: Hepatic impairment. Monitor patients for signs of increased drug exposure.

Please see Full Prescribing Information pdf opensfull Prescribing Information, including Instructions for Use.

References:

Full Prescribing Information for XHANCE (fluticasone propionate). OptiNose US, Inc.; 2023.
Djupesland PG. Nasal drug delivery devices: characteristics and performance in a clinical perspective — a review. Drug Deliv Transl Res. 2013;3(1):42-62.
Data on file. OptiNose US, Inc.
Newton JR, Ah-See KW. A review of nasal polyposis. Ther Clin Risk Manag. 2008;4(2):507-512.